The research question addressed by this report is, “What is the clinical effectiveness and costeffectiveness of fludarabine in B-cell CLL with sufficient bone marrow reserve and who have not responded to or whose disease has progressed during or after treatment with at least one standard alkylating-agent containing regimen?” these being the circumstances for which fludarabine is currently licensed.